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Abstract
Background: Serum g-glutamyltransferase activity (GGT),
even when within its normal reference range, catalyzes low
density lipoprotein oxidation in vitro and predicts cardiovas-
cular events. Of the four GGT fractions (b-GGT, m-GGT, s-
GGT, and f-GGT) recently identified in blood, only b-GGT
is found within atherosclerotic plaques. Our goal was to
identify the determinants of the GGT fractions (b-, m-, s-,
and f-GGT) and their association with established cardio-
vascular risk factors in healthy subjects.
Methods: Multiple linear regression analysis was applied to
estimate the association of fractional GGT with gender, age,
body mass index, arterial pressure (AP), plasma glucose, ala-
nine aminotransferase (ALT), high and low density lipopro-
teins (LDL-C) cholesterol (HDL-C), triglycerides (TG) and
C-reactive protein (CRP) in 200 healthy subjects.
Results: All GGT fractions were associated with ALT; b-
GGT with AP, TG, and CRP; m-GGT with LDL-C, TG and
CRP; s-GGT with TG and CRP, and f-GGT only with LDL-
C, whereas gender was associated with s-GGT and f-GGT
only.
Conclusions: In healthy individuals, cardiovascular risk fac-
tors are associated with high molecular weight GGT frac-
tions, namely with b-GGT, the only form present within the
plaque. This finding adds to the present knowledge concern-
ing the relevance of GGT, within its reference range, for
atherosclerosis-related events.
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Introduction
Serum g-glutamyltransferase (GGT) activity that is within
its normal reference range was found to predict the risk of
onset and evolution of atherosclerotic processes (1–3) and
related diseases, such as hypertension (4, 5), type 2 diabetes
(6–9), and metabolic syndrome (10). Evidence of the asso-
ciation between total serum GGT activity and coronary
artery disease related events, infarction and stroke was
achieved either in unselected populations (11–13) or in
patients with known cardiovascular disease (14), thus con-
firming earlier epidemiological observations showing the
predictive value of GGT for overall and cardiac mortality
(15–17). GGT has been proposed as a marker of oxidative
stress and exposure to xenobiotics (18, 19). Biochemical and
pathology studies conducted in our laboratory showed that
GGT activities within the reference range catalyze oxidative
reactions in the presence of iron ions that lead to the pro-
duction of free radicals and reactive oxygen species and low
density lipoprotein (LDL) oxidation (20, 21). The potential
role of GGT in promoting plaque formation and evolution
has been confirmed by the identification of catalytically
active GGT in coronary, cerebral and carotid plaques, co-
localized with oxidized lipoproteins and CD68q foam cells
(2, 22). Plaque GGT has also been characterized. We recently
showed, using a novel high performance gel filtration chro-
matography method, that a) circulating GGT is comprised of
a combination of several distinct GGT-containing molecular
complexes wb-GGT, m-GGT, s-GGT, and f-GGT, with molec-
ular weight (MW) )2000, 940, 140, and 70 kDa, respec-
tivelyx, with s-GGT and f-GGT representing the greatest
fractions in the plasma of healthy subjects (23, 24), b) GGT
found in plaques has a MW that corresponds to b-GGT (25).
This study was performed to identify the determinants of
the plasma GGT fraction pattern, in particular b-GGT in
healthy subjects, and their association with established car-
diovascular risk factors.
Materials and methods
Subjects
Fasting blood samples were obtained between 08:00 and 09:00 h
from 200 healthy individuals wblood donors, 100 males, mean"
standard deviation (SD), age 44"10 years (range, 21–64 years),
100 females, age 40"11 years (range 20–64 years)x, following an
overnight fasting. The presence of acute or chronic diseases and of
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Table 1 Characteristics of the study population.
Males Females p-Value
(ns100) (ns100)
Age, years 44.0 (9.5) 39.9 (11.3) -0.01
BMI, kg/m2 25.8 (2.8) 23.6 (4.0) -0.0001
DAP, mm Hg 79.1 (6.1) 74.4 (7.2) -0.0001
SAP, mm Hg 122.1 (8.8) 117.7 (9.6) -0.001
Blood glucose, mmol/L 5.39 (0.57) 5.00 (0.57) -0.001
Creatinine clearance, mL/s 1.88 (0.44) 1.72 (0.43) -0.05
Uric acid, mmol/L 0.32 (0.07) 0.24 (0.06) -0.01
Total cholesterol, mmol/L 4.94 (1.00) 4.81 (1.04) n.s.
HDL-C, mmol/L 1.25 (0.34) 1.52 (0.39) -0.001
LDL-C, mmol/L 3.23 (0.84) 2.95 (0.88) n.s.
TG, mmol/L 1.16 (0.99) 0.84 (0.46) -0.001a
AST (GO), U/L 20.5 (5.2) 15.5 (4.5) -0.0001
ALT (GP), U/L 24.3 (9.8) 13.6 (6.0) -0.0001
Total GGT, U/L 30.6 (17.5) 16.1 (6.9) -0.001a
b-GGT, U/L 3.6 (3.3) 1.6 (1.6) -0.0001a
m-GGT, U/L 1.3 (1.2) 0.5 (0.3) -0.0001a
s-GGT, U/L 12.4 (11.4) 5.0 (3.9) -0.0001a
f-GGT, U/L 13.3 (3.7) 9.0 (2.4) -0.0001
Total bilirubin, mmol/L 14.67 (6.70) 11.92 (3.30) -0.001
Hemoglobin, g/L 156.81 (9.74) 137.45 (8.69) -0.0001
CRP, mg/L 1.53 (2.65) 1.90 (2.89) n.s.a
Leukocytes, =109 L 6.6 (1.7) 6.5 (1.5) n.s.
Data are mean (SD). aStudent’s t-test performed on ln-transformed data. BMI, body mass index; DAP, diastolic artery pressure; SAP, systolic
artery pressure; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; TG, triglycerides; AST, aspartate
aminotransferase; ALT, alanine aminotransferase; GGT, g-glutamyltransferse; CRP, C-reactive protein; n.s., not significant. Creatinine clear-
ance was estimated by the Cockroft-Gault formula; LDL-C was estimated by the Friedewald formula.
metabolic syndrome was excluded by history, clinical examination
and comprehensive laboratory testing. Metabolic syndrome was
assessed using World Health Organization (WHO) (26, 27) criteria.
These criteria used for this diagnosis were: fasting glucose
)6.11 mmol/L plus any two of the following: antihypertensive
medication and/or high blood pressure wdiastolic arterial pressure
(DAP) G90 mm Hg, systolic arterial pressure (SAP) G140 mm
Hgx, plasma triglycerides (TG) G1.69 mmol/L, high density lipo-
protein cholesterol (HDL-C) -0.91 mmol/L in men or
-1.01 mmol/L in women, body mass index (BMI) )30 kg/m2.
Subjects taking pharmacological treatment for whatever reasons or
with alcohol consumption )45 g/day for men and )30 g/day for
women were excluded from the study (ns37 males, 33 females);
59 males and 96 females were alcohol abstainers, 41 males with
daily alcohol consumption -45 g and four females with daily alco-
hol consumption -30 g. Of the 200 subjects, nine males (BMI
range: 30.1–35.5) and nine females (BMI range: 30.1–35.4) were
considered obese, and three males were pre-diabetic. According to
WHO recommendations, we set the limit of hazardous alcohol con-
sumption to -45 g/day for men and -30 g/day for women (28),
However, 40 g/day consumption was identified in three males only,
and 25 g/day consumption in one female, out of 200 control sub-
jects. Total and fractional GGT activities in this population had been
characterized previously (24). The study was approved by the Insti-
tutional Ethics Committee and all subjects gave informed consent.
Laboratory analyses
Analyses of all blood samples were performed simultaneously using
standard clinical laboratory procedures with automated analyzers
(Beckman Synchron CX 9-PRO analyzer, Beckman Coulter Italia,
Milan, Italy; Abbott Cell-Dyn Saphire for blood cell count, Abbott
Italia, Latina, Italy). LDL cholesterol (LDL-C) and creatinine clear-
ance were calculated using the Friedewald and the Cockcroft-Gault
formula, respectively. High sensitivity C-reactive protein (CRP) was
measured using the hsC Immunolite kit (Siemens Healthcare Diag-
nostics, Milan, Italy).
Analysis of total and fractional GGT was performed using plas-
ma-EDTA (ethylenediaminetetraacetic acid) samples as described
previously (23, 24) using an FPLC (fast protein liquid chromato-
graphy) system (AKTA purifier, GE Healthcare Europe, Milan, Ita-
ly) equipped with a gel filtration column (Superose 6 HR 10/300
GL, GE Healthcare Europe) and fluorescence detector (Jasco FP-
2020, Jasco Europe, Lecco, Italy). GGT activity was measured using
g-glutamyl-7-amido-4-methylcoumarin (gGluAMC, Nova Chimica,
Milan, Italy) as substrate and glycylglycine as acceptor of the trans-
peptidation reaction. A 4.5 mmol/L stock solution of gGluAMC was
prepared in ethanol 30% w/w containing 0.005 N NaOH and stored
at –208C. This solution was diluted 25-fold into 0.25 M Tris-HCl
buffer pH 8.5 (258C) daily.
Statistics
Biological parameters and values of GGT fractions between healthy
males and females were compared using Student’s t-test. Gender-
specific analysis has been performed previously due to the well-
known difference in total GGT reference values and the potential
difference to the association with recognized confounders in healthy
subjects. To perform parametric statistical analysis, total, b-, m- and
s-GGT, triglyceride and CRP values were ln-transformed to reduce
skewness of the distribution. f-GGT fraction data were not ln-trans-
formed because they were normally distributed (24).
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Univariate linear correlations between biological variables, such
as gender, age, BMI, estimated creatinine clearance, arterial pressure
(AP), uric acid, plasma glucose, HDL-C and LDL-C, TG, aspartate
aminotransferase (AST), alanine aminotransferase (ALT), CRP, and
fractional GGT activity were presented as the Pearson correlation
coefficient, and linear regression analyses were performed to assess
associations. The association between alcohol consumption (consid-
ered as a dichotomous variable, that is individual consumption
greater than or less than 12 g/day) and total or fractional GGT was
analyzed using Student’s t-test in males. Significant ethanol use was
observed in three females only.
Multiple linear regression with total and fractional GGT activities
as dependent variables was performed to quantify the independent
effect of univariate significant factors. Results were presented as a
b-standardized coefficient. p-0.05 was considered significant. Sta-
tistical analysis was performed with SPSS 13 analysis software
(Copyright SPSS Inc.).
Results
Characteristics of subjects
Males showed significantly higher values for BMI, SAP,
DAP, blood glucose, creatinine clearance, uric acid, serum
TG, AST, ALT, total and fractional GGT, bilirubin, hemo-
globin and lower HDL-C compared with females (Table 1).
Total cholesterol and LDL-C, CRP levels and leukocytes
count were not different between the two populations.
Determinants of GGT fraction activity according
to gender
All GGT fractions were associated with ALT in both genders
(Table 2). All GGT fractions were associated with AST in
males, whereas in females AST was associated with m-GGT
and f-GGT only (Table 2). Total and fractional GGT was not
significantly associated with creatinine clearance in healthy
subjects (not shown).
In healthy males, all GGT fractions were associated with
uric acid, TG, AST, CRP and leukocyte count. In addition,
b-GGT activity was associated with BMI, DAP, LDL-C and
hemoglobin; m-GGT was associated with LDL-C and neg-
atively associated with HDL-C; s-GGT was associated with
hemoglobin; f-GGT was associated with BMI, DAP, LDL-C
and hemoglobin, while being negatively associated with
HDL-C. Moderate alcohol consumption did not significantly
influence total and fractional GGT in male subjects (Supple-
mental data Table 1).
In females, all GGT fractions were significantly associated
with SAP, DAP and hemoglobin. In addition, b-GGT activity
was associated with age, BMI, glucose, uric acid, LDL-C,
TG, CRP and leukocyte count; m-GGT was associated with
BMI, glucose, uric acid, LDL-C, TG, AST, CRP and leu-
kocyte count; s-GGT was associated with TG, CRP and leu-
kocyte count; f-GGT was associated with age, glucose,
LDL-C, AST and bilirubin (Table 2).
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Table 3 Multivariate linear regression analysis: independent predictors of GGT fraction activity in healthy subjects.
Gender DAP LDL-C TG ALT CRP
Total GGT 0.249a n.s. n.s. n.s. 0.432a 0.132b
b-GGT n.s. 0.153b n.s. 0.188c 0.379a 0.148b
m-GGT n.s. n.s. 0.283a 0.168c 0.394a 0.142b
s-GGT 0.255a n.s. n.s. 0.141b 0.448a 0.197c
f-GGT 0.273a n.s. 0.173c n.s. 0.290a n.s.
Data reported are b standardized coefficients. apF0.001, bp-0.05, cpF0.01. DAP, diastolic artery pressure; LDL-C, low density lipoprotein
cholesterol; TG, triglycerides; ALT, alanine aminotransferase; CRP, C-reactive protein; GGT, g-glutamyltransferase; n.s., not significant.
Independent predictors of GGT fraction activity
in healthy subjects
Total GGT was independently associated with gender, CRP
and ALT. The latter was independently associated with all
GGT fractions. TG and CRP were independently associated
with b-, m- and s-GGT; in addition DAP was associated only
with b-GGT, LDL-C with m-GGT and gender with s-GGT.
The latter two variables were positively associated also with
f-GGT (Table 3). No association was seen with respect to
age, BMI, glucose and HDL-C (data not shown).
Discussion
This work is the first to show that in healthy individuals,
GGT fractions show different associations with established
cardiovascular risk factors, namely those that are markers of
inflammation (CRP) and lipid metabolism.
In particular, while gender was found to correlate inde-
pendently only with the two low MW forms (s-GGT and f-
GGT), and ALT did not show specific association with any
GGT fraction, well-known cardiovascular risk factors, such
as DAP, CRP, TG and LDL-C correlated primarily with the
higher MW fractions (b-GGT, the form identified within ath-
erosclerotic plaques, and m-GGT).
GGT activities within the reference range display pro-oxi-
dant properties (21), being able to catalyze the oxidation of
LDL (20), and catalytically active GGT was found within
the plaque where it is co-localized with oxidized LDL and
CD68q foam cells (22). Furthermore, GGT activities within
the reference range predicts the risk of onset and evolution
of atherosclerotic processes (1–3).
A key point to explaining the link between GGT and car-
diovascular events is the relationship between GGT and sta-
bility of the atherosclerotic plaque and to establish how
circulating GGT contributes to GGT activity. Recent studies
show that GGT activity present in the plaque is proportional
to that found in blood, displaying the same MW of plasma
b-GGT. This suggests that only b-GGT can enter the arterial
wall and accumulate within the plaque (25). These results
are in agreement with the finding that increases in total GGT
activity, but within the reference values, is associated pri-
marily with an increase in s-GGT, b-GGT and m-GGT (24).
The main advantage of the FPLC method for analysis of
plasma GGT activity is the ability to directly quantify and
study the clinical significance of each fraction, independently
from the behavior of the other fractions.
Gender, the only well-known physiological determinant of
total GGT (1), was found to be an independent determinant
of the lower MW s-GGT and f-GGT fractions only, whereas
markers with known predictive value for cardiovascular
events (such as AP, TG, CRP) showed a common association
with the potentially atherogenic b-GGT, but not with f-GGT.
Despite that total GGT was recognized as a predictor of
diabetes and the metabolic syndrome (10), GGT fractions did
not show an independent association with BMI and serum
glucose. This suggests that the predictive value of GGT for
these conditions is not a mere consequence of glucose con-
centrations or metabolic overload on the liver. Instead, this
is due to the complex interplay between inflammation,
abnormal lipid metabolism and hepatocellular damage dem-
onstrated by high MW GGT fractions determinants (CRP,
ALT, TG, LDL-C). Notably, none of our healthy individuals
that we recruited fulfilled criteria for the metabolic syn-
drome, and alcohol consumption did not influence GGT frac-
tional values. Measurement of waist circumference, which
has not been obtained in this subset, is well correlated with
intra-abdominal visceral adipose tissue accumulation, and
could add relevant information.
These studies were performed in a highly selected group
of apparently healthy individuals. It is questionable whether
this information applies to the understanding of the potential
association of subfractions of GGT with cardiovascular dis-
ease. For this purpose, follow-up of these findings in cohort
studies with validated end points (cardiovascular morbidity
and mortality) should be performed. These findings might
help in the understanding of the pathogenetic association
between GGT activity and cardiovascular disease. In addi-
tion, the ability to assess GGT fractions will help overcome
the limit represented by low specificity of serum GGT deter-
mination either for diagnostic or prognostic purposes.
Supplementary data associated with this article can be found in the
online version at: http://www.reference-global.com/doi/suppl/
10.1515/CCLM.2009.125.
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Supplemental Data
Supplementary Table 1 Total and fractional GGT activity in healthy males, either abstainers, or with moderate alcohol use wmean (SD):
18.2 (11.7) g/dayx.
Abstainers (ns59) Alcohol users (ns41) p-Value
Median Range Median Range
Total GGTa 24.7 12.1–60.6 26.1 14.8–52.6 n.s.
b-GGTa 2.3 0.6–11.8 2.5 1.2–8.7 n.s.
m-GGTa 0.9 0.3–2.8 1.3 0.2–3.3 n.s.
s-GGTa 7.3 2.4–33.9 10.3 3.5–25.4 n.s.
f-GGT 12.4 7.8–19.6 13.7 9.2–19.6 n.s.
Data are expressed as U/L. at-Test performed on ln-transformed data. n.s., not significant.
